Prior to joining Terremoto, James served as Chief Scientific Officer at Mirati where he was responsible for drug discovery, early clinical development and translational research, drug manufacturing and companion diagnostics. At Mirati, he led activities related to the discovery and advancement of the company’s clinical and preclinical programs, including adagrasib (KRAS^G12C selective inhibitor), MRTX1133 (KRAS^G12D selective inhibitor) and MRTX1719 (MTA-cooperative PRMT5 inhibitor).

Prior to Mirati, James was the head of Oncology Precision Medicine and a member of the executive leadership team in the Oncology Research Unit at Pfizer. In that role he was responsible for leading oncology nonclinical research and translational sciences for programs including Sutent^® and Xalkori^®. He also held positions at SUGEN/Pharmacia as a Group Leader on the Preclinical Research and Exploratory Development team. He began his industry experience at Warner Lambert/Parke-Davis.

James has authored or co-authored over 200 peer-reviewed research articles in scientific journals including Science, Nature, Cancer Cell, Cancer Discovery, New England Journal of Medicine and many others. In addition, he also participates on the editorial boards for the American Association for Cancer Research’s Cancer Research and Molecular Cancer Therapeutics journals. James is currently a Venture Partner at OrbiMed and is a member of the Board of Directors at Boundless Bio.

James received his Ph.D. at North Carolina State University and his B.S. in biology from Northern Illinois University.